Respiratory Biotech: Vertex CF Moat, IPF Graveyard, PAH Bet

Oncology gets the ASCO headlines and obesity gets the GLP-1 market-sizing estimates, but nobody ranks the lungs. That is the opening. The respiratory shelf spans three distinct pricing regimes: Vertex’s cystic fibrosis monopoly, Merck’s pulmonary arterial hypertension franchise, and the race to the first disease-modifying drug in idiopathic pulmonary fibrosis. One of those regimes has a real moat. One is a rounding error on a $372 billion stock. The third just lost its leader. Here is the ranking.

1. Vertex: the $13 billion CF moat that Sionna just proved is still unbreakable

Vertex closed Friday at $547.59 with a $138.8 billion market cap. Its cystic fibrosis franchise generates more than $13 billion in annual revenue from Trikafta and the newer Alyftrek, which together cover roughly 90% of CF patients carrying at least one F508del mutation. The most visible near-term threat to that franchise just died. Sionna Therapeutics’ SION-719, an NBD1 stabilizer meant to add benefit on top of Trikafta, produced a mean placebo-adjusted sweat chloride reduction of negative 1.0 mmol/L in its Phase 2a PreciSION trial. The p-value was 0.7. Analysts had said they wanted at least 5 to 7 mmol/L to consider the drug clinically meaningful. Sionna fell 90% on the news, and Vertex rose 6% as the moat widened.

The next threat is further out. 4D Molecular Therapeutics (FDMT, $15.39) is developing 4D-710, an aerosolized AAV gene therapy that delivers a codon-optimized CFTR transgene independent of the patient’s specific mutation. Interim Phase 1/2 AEROW data were positive enough that the Cystic Fibrosis Foundation committed $14 million in new funding. 4D-710 is the first genetic medicine to show CFTR delivery and expression throughout the airways after aerosol delivery, and the redosable, variant-agnostic pitch is exactly what would eventually threaten Vertex’s modulator economics. But it is Phase 1/2, years from a registrational readout, and the broader AAV field’s recent safety scares are a reminder that this frontier carries its own binary risk. For now, Vertex’s own next-generation corrector VX-828, reporting Phase 2 data in the second half of 2026, matters more to the franchise than 4D-710 does. Vertex is the only name on this shelf with a moat, and it is pivoting beyond CF to povetacicept and pain precisely because the CF market is already won. The valuation math is the real constraint: $138.8 billion in market cap against a $13 billion CF revenue base only works if the franchise keeps growing and the non-CF pivots start contributing real revenue.

2. Merck Winrevair: a real PAH franchise that cannot move a $372 billion stock

Merck (MRK, $150.66) has turned Winrevair (sotatercept) into the first genuine franchise in pulmonary arterial hypertension since the prostacyclin class. First approved in March 2024, sotatercept is an activin signaling inhibitor that produced a 76% reduction in the composite risk of clinical worsening versus placebo in its registrational program, a result no vasodilator in the field has matched. The FDA has since expanded the indication, the EU CHMP has issued a positive opinion for expanded use, and Merck is now running Phase 3 trials to push Winrevair into additional PAH settings. That is the good news. The bad news for anyone trading the name is that Winrevair’s growth is immaterial against a $371.7 billion market cap, so the approval trajectory does not move the stock the way a pure-play catalyst would.

The read-through from Gossamer Bio explains why most PAH challengers die. Gossamer’s seralutinib missed the primary endpoint of its Phase 3 PROSERA trial, the change in six-minute walk distance at Week 24, in February 2026, and the company plans to file an NDA anyway, a Hail Mary that has left the stock at $0.175 with a $90 million market cap. Sotatercept works because it targets the underlying activin pathway rather than patching symptoms; seralutinib, a PDGFR/CSF1R inhibitor, did not clear the walk-distance bar the field has used for decades. Merck’s franchise is real, but the investable point is that it is a diversified mega-cap holding, not a PAH trade.

3. IPF: the first-mover race is already over, and the winner is private

Idiopathic pulmonary fibrosis is the cruelest lane on this shelf: a progressive scarring disease with a median survival of three to five years, where the two approved antifibrotics, nintedanib and pirfenidone, only slow decline. The race to the first disease-modifying drug looked crowded a year ago. It is not anymore. Pliant Therapeutics’ bexotegrast, the lead integrin inhibitor, was discontinued in IPF in June 2025 after the BEACON-IPF trial showed an unfavorable risk-benefit profile, with an increased rate of IPF-progression events and an average time to disease progression of just 33 weeks. That was a safety failure, not an efficacy failure: bexotegrast actually improved FVC decline by 72 mL at Week 12. Pliant now trades at $1.14 with a $70 million market cap, and FibroGen’s pamrevlumab had already failed before it. The IPF graveyard is real.

The winner is Boehringer Ingelheim’s nerandomilast, a PDE4B inhibitor whose FIBRONEER-IPF Phase 3 met its primary endpoint: an adjusted 68.8 mL FVC benefit at the 18 mg dose versus placebo (negative 114.7 mL versus negative 183.5 mL, p less than 0.001), with the 9 mg dose adding 44.9 mL (p equal to 0.02), published in the New England Journal of Medicine. Its sister trial, FIBRONEER-ILD, met the same endpoint in progressive pulmonary fibrosis. The safety picture is mixed in an interesting way: diarrhea hit 41.3% of patients on the 18 mg dose versus 16% on placebo, and the key secondary composite endpoint was not met, but fatal adverse events ran at 2% on the 18 mg dose versus 5% on placebo. The drug slows lung-function decline; it just gives some patients a difficult gut to live with while it works. More important for investors: Boehringer Ingelheim is privately held. The IPF market is real, the mechanism is now validated, and there is no US pure-play to buy.

4. Asthma and COPD: the incumbents are fine, and they are not catalysts

Severe asthma is already won. Dupixent (Regeneron at $828.50 and Sanofi at $45.69) and Tezspire (AstraZeneca at $166.71 and Amgen at $443.84) own the biologic lane, and their label-expansion cadence is steady rather than catalytic. Sanofi’s recent pipeline cuts are a reminder that Dupixent is now the company’s entire growth story, but nothing on the asthma shelf is a near-term stock-mover. The respiratory-infectious overlay, the RSV vaccine battle between GSK, Moderna, and Pfizer, is a separate trade with a separate risk profile.

The risks

Vertex’s risk is concentration: CF is the majority of revenue, and the povetacicept and pain pivots are unproven at commercial scale. Merck’s risk is that Winrevair growth decelerates as the PAH field saturates and challengers keep filing. The IPF risk is that nerandomilast’s diarrhea profile and missed secondary endpoint limit real-world uptake, and that the eventual US commercial winner could be a name not yet on anyone’s radar.

The verdict

Own Vertex. It is the only name on the lung shelf with a moat, a $13 billion revenue base, and a catalyst, VX-828 Phase 2, that could actually extend the franchise. Treat Merck as a diversified mega-cap with a nice PAH tailwind, not a catalyst play. Skip the IPF lane entirely unless you can buy Boehringer Ingelheim, which you cannot. And do not touch Gossamer, a $90 million company betting its last chips on a missed-endpoint NDA. The pattern across all three regimes is the same one you see in oncology and rare disease: the winner is the company with an unassailable franchise. Pliant died on safety, Gossamer failed on efficacy, and Boehringer won the mechanism but remains private, so there is no ticker to buy. The lung shelf is one monopoly and a graveyard, and the ranking reflects it.